

Wednesday, December 11, 2013

9:15 a.m. - 9:30 a.m.

Location: Exhibit Hall D

General Session 1:

Program #S1-03 (Oral)

Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer.

Contributors:

Slamon DJ, Swain SM, Buysse M, Martin M, Geyer CE, IM Y-H, Pienkowski T, Kim SB, Robert NJ, Steger G, Crown J, Verma S, Eiermann W, Costantino JP, Im SA, Mamounas EP, Schwartzberg L, Paterson A, Mackey JR, Provencher L, Press MF, Thirlwell M, Bee-Munteanu V, Henschel V, Crepelle-Flechais A, Wolmark N

4:15 p.m. - 4:30 p.m.

Location: Exhibit Hall D

General Session 2:

Program #S2-05 (Oral)

10-yr follow-up results of occult detected sentinel node disease: NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patient.

Contributors:

Julian TB, Anderson SJ, Krag DN, Weaver DL, Costantino J, Ashikaga T, Harlow SP, Mamounas EP, Wolmark N.

5:00 p.m. - 7:00 p.m.

Location: Ballroom B

Poster Discussion 2:

Body Mass, Exercise, and Breast Cancer

Discussion 6:00 - 7:00 p.m.

Program #PS2-1

Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38.

Contributors:

Cecchini RS, Swain SM, Costantino JP, Rastogi P, Jeong J, Anderson SJ, Geyer CE Jr, Lembersky BC, Romond EH, Paterson AH, Wolmark N

5:00 p.m. - 7:00 p.m.

Location: Exhibit Halls A-B

Poster Session 1:

Ongoing Clinical Trials 1

HER2 - Program #OT1-1-06

A phase 3 randomized open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy. (B-50-1/ KATHERINE)

Contributors:

Geyer CE, Loibl S, Mamounas EP, Untch M, Wolmark N, Huang C-S, Mano M, Zheng M, Smitt M, von Minckwitz G

Thursday, December 12, 2013

5:00 p.m. - 7:00 p.m.

Location: Exhibit Halls A-B

Poster Session 3:

Ongoing Clinical Trials 2

DCIS - Program #OT1-1-06

NSABP B-43: A phase III clinical trial to compare trastuzumab given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy.

Contributors:

Cobleigh MA, Anderson SJ, Julian TB, Siziopikou KP, Arthur DW, Rabinovitch R, Zheng P, Mamounas EP, Wolmark N

Friday, December 13, 2013

5:00 p.m. - 7:00 p.m.

Location: Exhibit Halls A-B

Poster Session 5:

Treatment - other

Program #P5-17-01

A definition of a high-risk early-breast cancer population based on data from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) meta-analysis.

Contributors:

Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, Bonnefoi H, Piccart M, Gianni L, Valagussa P, Zujewski J, Justice R, Loibl S, Swain SM, Bogaerts J, Baselga J, Prowell TM, Rastogi P, Sridhara R, Tang S, Pazdur R, Mamounas EP, von Minckwitz G